MX2021012166A - Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano. - Google Patents

Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano.

Info

Publication number
MX2021012166A
MX2021012166A MX2021012166A MX2021012166A MX2021012166A MX 2021012166 A MX2021012166 A MX 2021012166A MX 2021012166 A MX2021012166 A MX 2021012166A MX 2021012166 A MX2021012166 A MX 2021012166A MX 2021012166 A MX2021012166 A MX 2021012166A
Authority
MX
Mexico
Prior art keywords
lysines
derivatives
activity against
human serum
gram
Prior art date
Application number
MX2021012166A
Other languages
English (en)
Spanish (es)
Inventor
Raymond Schuch
Original Assignee
Contrafect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corp filed Critical Contrafect Corp
Publication of MX2021012166A publication Critical patent/MX2021012166A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MX2021012166A 2019-04-05 2020-04-03 Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano. MX2021012166A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962830207P 2019-04-05 2019-04-05
PCT/US2020/026681 WO2020206327A1 (en) 2019-04-05 2020-04-03 Lysins and derivatives thereof with bactericidal activity against pseudomonas aeruginosa, in the presence of human serum

Publications (1)

Publication Number Publication Date
MX2021012166A true MX2021012166A (es) 2021-11-03

Family

ID=72667504

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012166A MX2021012166A (es) 2019-04-05 2020-04-03 Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano.

Country Status (11)

Country Link
US (1) US20220160843A1 (https=)
EP (1) EP3946609A4 (https=)
JP (1) JP2022526978A (https=)
KR (1) KR20210148320A (https=)
CN (1) CN114040773A (https=)
AU (1) AU2020256258A1 (https=)
BR (1) BR112021019430A2 (https=)
CA (1) CA3136126A1 (https=)
IL (1) IL286941A (https=)
MX (1) MX2021012166A (https=)
WO (1) WO2020206327A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24750B1 (es) * 2020-11-19 2025-06-11 Centro De Investig Y Desarrollo De Medicamentos Cidem Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes
CN116200418A (zh) * 2021-12-01 2023-06-02 华南农业大学 一种筛选铜绿假单胞菌LasR基因调控网络未知基因突变体的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5701777B2 (ja) * 2009-02-06 2015-04-15 テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー 抗菌性ファージ、ファージペプチド、及びそれらの使用方法
CA2833409A1 (en) * 2011-04-21 2012-10-26 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
AU2015279705B2 (en) * 2014-06-26 2021-04-01 The Rockefeller University Acinetobacter lysins
AU2016324307B2 (en) * 2015-09-17 2021-10-21 Contrafect Corporation Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
BR112020011433A2 (pt) * 2017-12-12 2020-12-01 Contrafect Corporation identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa
CN108103050A (zh) * 2018-02-11 2018-06-01 中国医药集团总公司四川抗菌素工业研究所 一种铜绿假单胞菌噬菌体裂解酶、其编码基因、重组表达载体及其制备方法和应用
CN112368376A (zh) * 2018-03-29 2021-02-12 康特拉费克特公司 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途
WO2020046747A1 (en) * 2018-08-23 2020-03-05 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof

Also Published As

Publication number Publication date
CA3136126A1 (en) 2020-10-08
EP3946609A1 (en) 2022-02-09
EP3946609A4 (en) 2023-05-03
US20220160843A1 (en) 2022-05-26
BR112021019430A2 (pt) 2021-11-30
KR20210148320A (ko) 2021-12-07
AU2020256258A1 (en) 2021-11-04
JP2022526978A (ja) 2022-05-27
WO2020206327A1 (en) 2020-10-08
IL286941A (en) 2021-10-31
CN114040773A (zh) 2022-02-11

Similar Documents

Publication Publication Date Title
MX2020006098A (es) Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano.
Boparai et al. Mini review on antimicrobial peptides, sources, mechanism and recent applications
Oelkrug et al. Mode of action of anticancer peptides (ACPs) from amphibian origin
Shagaghi et al. Archetypal tryptophan-rich antimicrobial peptides: properties and applications
Veldhuizen et al. Antimicrobial and immunomodulatory activities of PR-39 derived peptides
Ong et al. Effect of stereochemistry, chain length and sequence pattern on antimicrobial properties of short synthetic β-sheet forming peptide amphiphiles
Blower et al. Snake cathelicidin NA-CATH and smaller helical antimicrobial peptides are effective against Burkholderia thailandensis
Liu et al. Design of novel antimicrobial peptide dimer analogues with enhanced antimicrobial activity in vitro and in vivo by intermolecular triazole bridge strategy
MX2020010076A (es) Construcciones de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos.
MX2019004439A (es) Nuevos agentes antimicrobianos contra las bacterias enterococcus.
MX2021012166A (es) Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano.
Baranska-Rybak et al. Safety profile of antimicrobial peptides: camel, citropin, protegrin, temporin a and lipopeptide on HaCaT keratinocytes
WO2019077634A3 (en) Therapeutic compositions of antimicrobial peptides
Tanhaeian et al. Expression of thanatin in HEK293 cells and investigation of its antibacterial effects on some human pathogens
Sim et al. A significantly enhanced antibacterial spectrum of D-enantiomeric lipopeptide bactenecin
BR112021025948A2 (pt) Polipeptídeos antimicrobianos derivados de bacteriófagos e seu uso contra bactérias gram-negativas e ácido-resistentes
Mohan et al. Enhanced antimicrobial activity of peptide-cocktails against common bacterial contaminants of ex vivo stored platelets
US20160022832A1 (en) Proteas stabilized antibacterial peptides for s. aureus
Ouyang et al. High therapeutic index α-helical AMPs and their therapeutic potential on bacterial lung and skin wound infections
Bommineni et al. A fowlicidin-1 analog protects mice from lethal infections induced by methicillin-resistant Staphylococcus aureus
Harris et al. Anionic antimicrobial peptides from eukaryotic organisms and their mechanisms of action
WO2018231058A3 (en) ANTIMICROBIAL PEPTIDES AND THEIR MIXTURES HAVING ANTIMICROBIAL ACTIVITY AGAINST NEGATIVE GRAM PATHOGENS
MX2021009443A (es) Composiciones que contienen bacterias productoras de bacillaeno o preparaciones de las mismas.
JOP20240271A1 (ar) ببتيدات إظهار أنشطة منع فقدان العضلات وتعزيز الكتلة العضلية واستخداماتها
Kormilets et al. Antibiotic peptides